Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLS-M22
- Development stage
- Phase 1
- Lead developer
- MOA Life Plus
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Silencing → Gene Therapies, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Editing → Gene Therapies, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Addition/Replacement → Gene Therapies
- Administration
- Oral
01
Overview
BLS-M22 is an investigational oral therapeutic vaccine developed for the treatment of Duchenne muscular dystrophy (DMD). It consists of a recombinant strain of *Lactobacillus casei* engineered to express a modified human myostatin gene, using the MucoMax technology platform. The therapy works by inducing the production of anti-myostatin antibodies in the host, thereby inhibiting myostatin—a negative regulator of muscle growth and member of the transforming growth factor-beta superfamily. Preclinical studies in *mdx* mice (a model for DMD) have shown that oral administration of BLS-M22 increases anti-myostatin IgG titers, reduces serum creatine kinase levels, improves muscle histology, and enhances motor function. The drug has received orphan drug designation for DMD but remains investigational with no reported approvals[1][3][6].
- Other names
- BLS-M22BLS-M-22BLS-M 22BLS M22
02
Targets
GDF8 (Myostatin)
Beyond the preview
Go deeper on BLS-M22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BLS-M22.